<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984178</url>
  </required_header>
  <id_info>
    <org_study_id>2004-005149-36</org_study_id>
    <secondary_id>PI041078</secondary_id>
    <nct_id>NCT00984178</nct_id>
  </id_info>
  <brief_title>Trial of Hematopoietic Stem Cells in Acute Myocardial Infarction</brief_title>
  <acronym>TECAM2</acronym>
  <official_title>Randomized Trial Comparing Intracoronary Delivery of Bone Marrow-derived Stem Cells Versus Stem Cell Mobilisation With GCSF, a Combination of Both Therapies and Conventional Treatment in Patients With Reperfused Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TECAM Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TECAM Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effectiveness of four different strategies for&#xD;
      preventing the ventricular postinfarction remodelling: 1) Conventional treatment for&#xD;
      reperfunded extensive acute myocardial infarction, 2) Autologous bone marrow stem-cells&#xD;
      intracoronary transplantation 3) mobilization of bone marrow stem-cells induced by&#xD;
      granulocyte colony-stimulating factors (G-CSF); and 4) combined treatment (stem-cells&#xD;
      transplantation plus mobilization with G-CSF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study is a phase II randomized trial for patients with an acute extensive&#xD;
      reperfunded myocardial infarction who undergo coronary artery revascularization with&#xD;
      sirolimus coated stents. The aim of this study is to compare the effectiveness of four&#xD;
      different strategies for preventing the ventricular postinfarction remodelling: 1)&#xD;
      Conventional treatment for reperfunded extensive acute myocardial infarction, 2) Autologous&#xD;
      bone marrow stem-cells intracoronary transplantation 3) mobilization of bone marrow&#xD;
      stem-cells induced by granulocyte colony-stimulating factors (G-CSF); and 4) combined&#xD;
      treatment (stem-cells transplantation plus mobilization with G-CSF). The investigational&#xD;
      follow-up will be at 30 days, 4 and 9 months.Effectiveness of the therapies on neomyogenesis&#xD;
      will be measured by Magnetic Resonance Imaging analysis of left ventricular size and global&#xD;
      and regional function and the myocardial viability.The impact of the therapies on stent&#xD;
      re-endothelialization and restenosis will be analysed by angiography and intracoronary&#xD;
      ultrasounds at 30 days and 9 months. The impact of the different treatments on&#xD;
      neoangiogenesis will be measured by infarct related artery intracoronary study of the&#xD;
      evolution of coronary flow reserve. Also, it will be measured the haematopoietic precursors&#xD;
      kinetic in the different treatment branches.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in left ventricular ejection fraction and left ventricular end-systolic volume relative to baseline measured by magnetic resonance</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in left ventricle end-dyastolyc volume, segment contractility, wall thickness and intravascular ultrasound reendothelization relative to baseline measured by magnetic resonance and other imaging techniques</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety of the study procedures</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Reperfused Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone marrow mononuclear progenitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intracoronary transplantation of bone-marrow mononuclear progenitor cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GCSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GCSF plus bone marrow mononuclear cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Granulocite Colony Stimulating Factor treatment (G-CSF)</intervention_name>
    <description>G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days</description>
    <arm_group_label>GCSF</arm_group_label>
    <arm_group_label>GCSF plus bone marrow mononuclear cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone marrow mononuclear cells</intervention_name>
    <description>Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration</description>
    <arm_group_label>Bone marrow mononuclear progenitors</arm_group_label>
    <arm_group_label>GCSF plus bone marrow mononuclear cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 75 years&#xD;
&#xD;
          -  Acute myocardial infarction with the following characteristics:&#xD;
&#xD;
               -  Clinical symptoms of chest pain lasting &gt;30 minutes, unresponsive to&#xD;
                  nitroglycerin.&#xD;
&#xD;
               -  Typical myocardial enzymatical necrotic curve&#xD;
&#xD;
               -  Total summed ST-segment elevation ≥ 6 mm in 12-lead electrocardiogram.&#xD;
&#xD;
          -  Akynesis or hypokinesis in infarct-related artery area without contractility&#xD;
             abnormalities in the rest of areas.&#xD;
&#xD;
          -  Pharmacological, mechanical or both type reperfusions (facilitated angioplasty) with&#xD;
             evidence of normal infarcted area epicardial flow (TIMI grade 3) in the first 24 hours&#xD;
             after the beginning of the symptoms&#xD;
&#xD;
          -  Successful repair of the infarct-related artery (residual post-stenting stenosis &lt; 30%&#xD;
             by visual estimation with epicardial normal flow [grade 3] in the first 24 hours after&#xD;
             the beginning of the symptoms or lack of significant residual lesions evidence (&lt;50%&#xD;
             visual estimation) in infarct-related artery.&#xD;
&#xD;
          -  Lack of evidence of significant lesions in the remaining coronary vessels or adequate&#xD;
             revascularization achieved in the first 24 hours after symptoms began.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of cardiogenic shock defined as sustained systolic blood pressure less&#xD;
             than 90 mm Hg, with no response to fluids or systolic blood pressure less than 100 mm&#xD;
             Hg with vasopressors (in absence of bradycardia)&#xD;
&#xD;
          -  Suspicion or evidence of infarct mechanical complication&#xD;
&#xD;
          -  History of sustained ventricular tachycardia or atrial fibrillation&#xD;
&#xD;
          -  Patient with cardiac defibrillator or candidate for its potential implantation.&#xD;
&#xD;
          -  Investigational drug treatment in the previous 4 weeks&#xD;
&#xD;
          -  Actual or potential use of anti-neoplastic drugs&#xD;
&#xD;
          -  Oncology antecedents in the last 5 years&#xD;
&#xD;
          -  Previous treatment with trans myocardial laser revascularization&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Severe concomitant disease modifying patient's survival during the study&#xD;
&#xD;
          -  Inability to suspend thrombolytic treatment&#xD;
&#xD;
          -  Active bleeding or major surgery within 2 weeks forbidding the use of heparin,&#xD;
             abciximab or antiplatelet therapy.&#xD;
&#xD;
          -  Previous malignant haematology disease (leukaemia or lymphomas) or hypercoagulability&#xD;
             disorders (antiphospholipid syndrome, antithrombin, C-protein and S-protein or V&#xD;
             Leiden Factor deficiency)&#xD;
&#xD;
          -  Previous known renal failure (creatinine &gt; 2.5 mg /dl)&#xD;
&#xD;
          -  Any kind of stroke in the last year or whenever episode of haemorrhagic stroke.&#xD;
&#xD;
          -  Major surgery pending in the next year&#xD;
&#xD;
          -  Previously known vascular disease that prevents from catheterization.&#xD;
&#xD;
          -  Evidence of hypersensitivity to Filgrastim, proteins derived from E. coli or any&#xD;
             formulation component.&#xD;
&#xD;
          -  Inability to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Fernandez-Aviles, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro L Sanchez, MD, PhD</last_name>
    <phone>34-915865882</phone>
    <email>pedrolsanchez@secardiologia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco Fernández-Aviles, MD, PhD</last_name>
    <phone>34-915865882</phone>
    <email>faviles@secardiologia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto San Roman, MD, PhD</last_name>
      <phone>34-665399285</phone>
      <email>asanroman@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Alberto San Roman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cardiovascularcelltherapy.com/</url>
    <description>Webmail of the TECAM group</description>
  </link>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Francisco Fernández-Avilés</name_title>
    <organization>TECAM</organization>
  </responsible_party>
  <keyword>Reperfusion</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>stem cell therapy</keyword>
  <keyword>GCSF</keyword>
  <keyword>bone marrow mononuclear cells</keyword>
  <keyword>magnetic resonance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

